Search results
Results from the WOW.Com Content Network
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.
Exact Sciences (NASDAQ: EXAS) Q3 2024 Earnings Call Nov 05, 2024, 5:00 p.m. ET. Contents: Prepared Remarks. ... On the call today are Kevin Conroy, the company's chairman and CEO; and Aaron ...
Included was a final decision related to CMS pricing for Exact Sciences Corp’s (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October. ... The company is ...
On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for ...
Genomic Health, Inc. is a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California. [2] The company was acquired by and merged with Exact Sciences Corporation in 2019.
EXAS earnings call for the period ending June 30, 2024.
Biomatrica, Inc. is a United States-based biotechnology company, and subsidiary of Exact Sciences Corporation, that develops chemicals for ambient temperature preservation of biological materials for the purpose of expanding the availability and accuracy of medical diagnostics and research.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.15% and 5.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?